Compare OSW & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSW | WGS |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | Bahamas | United States |
| Employees | N/A | 1300 |
| Industry | Hotels/Resorts | Retail: Computer Software & Peripheral Equipment |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.3B |
| IPO Year | 2019 | N/A |
| Metric | OSW | WGS |
|---|---|---|
| Price | $20.40 | $88.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $25.00 | ★ $140.71 |
| AVG Volume (30 Days) | ★ 2.0M | 710.5K |
| Earning Date | 05-21-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $961,001,000.00 | N/A |
| Revenue This Year | $7.49 | $29.98 |
| Revenue Next Year | $7.65 | $24.85 |
| P/E Ratio | ★ $30.29 | $1,251.58 |
| Revenue Growth | ★ 7.37 | N/A |
| 52 Week Low | $14.21 | $55.17 |
| 52 Week High | $23.54 | $170.87 |
| Indicator | OSW | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 39.88 | 49.00 |
| Support Level | $19.05 | $78.80 |
| Resistance Level | $22.93 | $95.94 |
| Average True Range (ATR) | 0.89 | 5.76 |
| MACD | -0.23 | 1.35 |
| Stochastic Oscillator | 9.63 | 80.83 |
OneSpaWorld Holdings Ltd is an operator of health and wellness centers onboard cruise ships and an operator of health and wellness centers at destination resorts all over the world. It offers a suite of premium health, fitness, beauty, and wellness services and products. The services provided by the company include body, salon, and skin care services and products, fitness classes and personal fitness training and pain management, detoxifying programs, and comprehensive body composition analyses among others. The company has only one single segment of Maritime and Destination Resorts.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.